A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight With Weight-Related Comorbidities

The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity

Inclusion Criteria:

• Age ≥ 18 and ≤ 75 years
• Have a BMI ≥27 kg/m² and ≤ 45 kg/m²
• Have had a stable body weight for the 3 months prior to randomization

Exclusion Criteria:

• Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity
• Have a prior or planned surgical treatment for obesity
• Have or plan to have endoscopic and/or device-based therapy for obesity
• Have any prior diagnosis of diabetes
• Have an electrocardiogram (ECG) with abnormalities
• Have a history of Major Depressive Disorder (MDD) or other severe psychiatric disorders within the last 2 years
• Have a history of suicide attempt.